The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Documented positivity by sputum Xpert MTB/RIF assay
Administration of current tuberculosis therapy (if any) for no more than 7 days (≤7) at the time of enrolment.
Negative on Xpert MTB/RIF assay
Resistance to rifampicin as detected by an Xpert MTB/RIF assay
Known resistance to isoniazid, rifampicin, or pyrazinamide
HIV positive
Seoul National University Hospital
Lead sponsor
Chonnam National University Hospital
Collaborator
National Medical Center, Seoul
Collaborator
Pusan National University Hospital
Collaborator
Pusan National University Yangsan Hospital
Collaborator
Seoul National University Bundang Hospital
Collaborator
SMG-SNU Boramae Medical Center
Collaborator
Severance Hospital
Collaborator
Korean Institute of Tuberculosis
Collaborator
International Tuberculosis Research Center
Collaborator
Korean Center for Disease Control and Prevention
Collaborator